Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

So close: remaining challenges to eradicating polio.

Toole MJ.

BMC Med. 2016 Mar 14;14:43. doi: 10.1186/s12916-016-0594-6.

2.

An Insight into Recombination with Enterovirus Species C and Nucleotide G-480 Reversion from the Viewpoint of Neurovirulence of Vaccine-Derived Polioviruses.

Zhang Y, Yan D, Zhu S, Nishimura Y, Ye X, Wang D, Jorba J, Zhu H, An H, Shimizu H, Kew O, Xu W.

Sci Rep. 2015 Nov 25;5:17291. doi: 10.1038/srep17291.

3.

Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.

Famulare M, Chang S, Iber J, Zhao K, Adeniji JA, Bukbuk D, Baba M, Behrend M, Burns CC, Oberste MS.

J Virol. 2015 Oct 14;90(1):317-31. doi: 10.1128/JVI.01532-15.

4.

Development of enhanced antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 vaccine encapsulated carrier.

Saeed MI, Omar AR, Hussein MZ, Elkhidir IM, Sekawi Z.

Hum Vaccin Immunother. 2015;11(10):2414-24. doi: 10.1080/21645515.2015.1052918.

PMID:
26186664
5.

An outbreak of type π vaccine-derived poliovirus in Sichuan province, China: emergence and circulation in an under-immunized population.

Wang HB, Fang G, Yu WZ, Du F, Fan CX, Liu QL, Hao LX, Liu Y, Zheng JS, Qin ZY, Xia W, Zhang SY, Yin ZD, Jing Q, Zhang YX, Huang RN, Yang RP, Tong WB, Qi Q, Guan XJ, Jing YL, Ma QL, Wang J, Ma XZ, Chen N, Zheng HR, Li YQ, Ma C, Su QR, Reilly KH, Luo HM, Wu XP, Wen N, Yang WZ.

PLoS One. 2014 Dec 11;9(12):e113880. doi: 10.1371/journal.pone.0113880. eCollection 2014.

6.

Determinants of routine immunization coverage in Bungudu, Zamfara State, Northern Nigeria, May 2010.

Gidado S, Nguku P, Biya O, Waziri NE, Mohammed A, Nsubuga P, Akpan H, Oyemakinde A, Nasidi A, Suleman I, Abanida E, Musa Y, Sabitu K.

Pan Afr Med J. 2014 Jul 21;18 Suppl 1:9. doi: 10.11694/pamj.supp.2014.18.1.4149. eCollection 2014.

7.

Sequential asymptomatic enterovirus infections in a patient with major histocompatibility complex class II primary immunodeficiency.

Driss N, Mellouli F, Ben Yahia A, Touzi H, Barbouche MR, Triki H, Bejaoui M.

J Clin Microbiol. 2014 Sep;52(9):3486-9. doi: 10.1128/JCM.01122-14. Epub 2014 Jul 16.

8.

Limited and localized outbreak of newly emergent type 2 vaccine-derived poliovirus in Sichuan, China.

Yan D, Zhang Y, Zhu S, Chen N, Li X, Wang D, Ma X, Zhu H, Tong W, Xu W.

Clin Vaccine Immunol. 2014 Jul;21(7):1012-8. doi: 10.1128/CVI.00196-14. Epub 2014 May 21.

9.

Evolution and circulation of type-2 vaccine-derived polioviruses in Nad Ali district of Southern Afghanistan during June 2009-February 2011.

Sharif S, Abbasi BH, Khurshid A, Alam MM, Shaukat S, Angez M, Rana MS, Zaidi SS.

PLoS One. 2014 Feb 18;9(2):e88442. doi: 10.1371/journal.pone.0088442. eCollection 2014.

10.

Listening to the rumours: what the northern Nigeria polio vaccine boycott can tell us ten years on.

Ghinai I, Willott C, Dadari I, Larson HJ.

Glob Public Health. 2013;8(10):1138-50. doi: 10.1080/17441692.2013.859720. Epub 2013 Dec 3. Review.

11.

Emergence of vaccine-derived polioviruses, Democratic Republic of Congo, 2004-2011.

Gumede N, Lentsoane O, Burns CC, Pallansch M, de Gourville E, Yogolelo R, Muyembe-Tamfum JJ, Puren A, Schoub BD, Venter M.

Emerg Infect Dis. 2013 Oct;19(10):1583-9. doi: 10.3201/eid1910.130028.

12.
13.

High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies.

Driss N, Ben-Mustapha I, Mellouli F, Ben Yahia A, Touzi H, Bejaoui M, Ben Ghorbel M, Triki H, Barbouche MR.

Clin Vaccine Immunol. 2012 Oct;19(10):1684-9. Epub 2012 Aug 22.

14.

Detection of non-polio enteroviruses from 17 years of virological surveillance of acute flaccid paralysis in the Philippines.

Apostol LN, Suzuki A, Bautista A, Galang H, Paladin FJ, Fuji N, Lupisan S, Olveda R, Oshitani H.

J Med Virol. 2012 Apr;84(4):624-31. doi: 10.1002/jmv.23242.

15.

Antiviral activity of 3(2H)- and 6-chloro-3(2H)-isoflavenes against highly diverged, neurovirulent vaccine-derived, type2 poliovirus sewage isolates.

Shulman LM, Sofer D, Manor Y, Mendelson E, Balanant J, Salvati AL, Delpeyroux F, Fiore L.

PLoS One. 2011;6(5):e18360. doi: 10.1371/journal.pone.0018360. Epub 2011 May 25.

16.

Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Chen Z, Chumakov K, Dragunsky E, Kouiavskaia D, Makiya M, Neverov A, Rezapkin G, Sebrell A, Purcell R.

J Virol. 2011 May;85(9):4354-62. doi: 10.1128/JVI.02553-10. Epub 2011 Feb 23.

17.

Natural type 3/type 2 intertypic vaccine-related poliovirus recombinants with the first crossover sites within the VP1 capsid coding region.

Zhang Y, Zhu S, Yan D, Liu G, Bai R, Wang D, Chen L, Zhu H, An H, Kew O, Xu W.

PLoS One. 2010 Dec 21;5(12):e15300. doi: 10.1371/journal.pone.0015300.

18.

From emergence to eradication: the epidemiology of poliomyelitis deconstructed.

Nathanson N, Kew OM.

Am J Epidemiol. 2010 Dec 1;172(11):1213-29. doi: 10.1093/aje/kwq320. Epub 2010 Oct 26. Review.

19.

Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in Kenya.

Khetsuriani N, Helfand R, Pallansch M, Kew O, Fowlkes A, Oberste MS, Tukei P, Muli J, Makokha E, Gary H.

BMC Infect Dis. 2009 Aug 23;9:136. doi: 10.1186/1471-2334-9-136.

20.

Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, Argentina.

Mueller JE, Bessaud M, Huang QS, Martinez LC, Barril PA, Morel V, Balanant J, Bocacao J, Hewitt J, Gessner BD, Delpeyroux F, Nates SV.

Appl Environ Microbiol. 2009 Mar;75(5):1395-401. doi: 10.1128/AEM.02201-08. Epub 2009 Jan 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk